Skip to Main Content
Table 3

Number of cases/controls and ORsa of cancer according to predicted mEH activity and GSTM3 genotype

Oral/pharyngeal cancer patientsbLaryngeal cancer patientsc
Predicted mEH activityPredicted mEH activity
LowIntermediateHighLowIntermediateHigh
GSTM3 AA 1 (Reference) 2.4 (1.2–4.8) 1.6 (0.7–4.1) 1 (Reference) 2.0 (1.0–4.1) 1.1 (0.4–3.1) 
 Cases/controls 30/62 40/41 15/17 28/62 35/41 12/17 
GSTM3 AB or BB 1.1 (0.4–2.8) 0.9 (0.4–2.3) 4.2 (1.0–16.9) 2.0 (0.8–5.5) 2.2 (1.0–5.2) 13.1 (3.5–48.4) 
 Cases/controls 18/10 12/21 8/5 13/18 22/21 13/5 
Oral/pharyngeal cancer patientsbLaryngeal cancer patientsc
Predicted mEH activityPredicted mEH activity
LowIntermediateHighLowIntermediateHigh
GSTM3 AA 1 (Reference) 2.4 (1.2–4.8) 1.6 (0.7–4.1) 1 (Reference) 2.0 (1.0–4.1) 1.1 (0.4–3.1) 
 Cases/controls 30/62 40/41 15/17 28/62 35/41 12/17 
GSTM3 AB or BB 1.1 (0.4–2.8) 0.9 (0.4–2.3) 4.2 (1.0–16.9) 2.0 (0.8–5.5) 2.2 (1.0–5.2) 13.1 (3.5–48.4) 
 Cases/controls 18/10 12/21 8/5 13/18 22/21 13/5 
a

Data on smoking and/or alcohol drinking were missing for eight control individuals, six oral/pharyngeal cancer cases, and six laryngeal cancer cases; ORs adjusted for sex-, age-, smoking-, and alcohol-related variables.

b

Interaction test between predicted mEH activity and GSTM3 genotype (likelihood ratio test, 2 df): P = 0.08.

c

Interaction test between predicted mEH activity and GSTM3 genotype (likelihood ratio test, 2 df): P = 0.03.

Close Modal

or Create an Account

Close Modal
Close Modal